Abnormal levels of plasma hormones in men with prostate cancer: Evidence toward a “two-disease” theory

Authors

  • Dr. Barnett Zumoff,

    Corresponding author
    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    • Division of Endocrinology and Metabolism, Department of Medicine, Beth Israel Medical Center, 10 Nathan D. Perlman Place, New York, NY 10003
    Search for more papers by this author
  • Joseph Levin,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Gladys W. Strain,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Robert S. Rosenfeld,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • John O'Connor,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Selwyn Z. Freed,

    1. Department of Urology, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Jacob Kream,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Willet S. Whitmore,

    1. Department of Urology, Memorial Sloan-Kettering Medical Center, New York
    Search for more papers by this author
  • David K. Fukushima,

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author
  • Leon Hellman

    1. Clinical Research Center, Montefiore Hospital and Medical Center, Bronx, New York
    2. Institute for Steroid Research, Montefiore Hospital and Medical Center, Bronx, New York
    Search for more papers by this author

Abstract

The 24-hr mean plasma concentrations of 13 hormones or hormone metabolites (cortisol, testosterone, dihydrotestosterone, dehydroisoandrosterone, dehydroisoandrosterone sulfate, androsterone, androsterone sulfate, estrone, thyroxine, triiodothyronine, LH, FSH, and prolactin) were measured in 16 rigorously screened patients (aged 55–80) with stage C or D prostate cancer and 36 normal men. Nine of the hormones showed no abnormalities in the patients but four (testosterone, dihydrotestosterone, cortisol, and estrone) showed abnormalities. Testosterone and dihydrotestosterone, which, respectively, decreased with age and showed no change with age in the normal men, rose sharply with age in the patients. The patients' curves crossed the normal curves at about age 65; patients 65 or above showed normal values while patients under age 65 showed significantly subnormal levels of both hormones: testosterone averaged 282 ng/dl in patients vs 434 ng/dl in controls (P < 0.0001) and dihydrotestosterone averaged 70 ng/dl in patients vs 99 ng/dl in controls (P <0.01). Cortisol, which was age invariant in the normal men, fell sharply with age in the patients; patients under 65 had significantly elevated levels (10.1 vs 6.9 μg/dl; P < 0.0001), while patients 65 or older had normal levels. Estrone levels were age invariant in both patients and controls, but the mean level in patients was markedly elevated (81 vs 47 pg/ml in controls; P < 0.001). The cortisol/testosterone ratio almost completely separated prostate cancer patients under 65 from normal men, but did not discriminate patients 65 or older from normal.

The findings indicate that prostate cancer patients under 65 differ markedly in their endogenous hormonal pattern from patients 65 or older. This leads us to propose a “two-disease” theory of prostate cancer, with possible differences in genetic factors and prognosis.

Ancillary